Prior studies have suggested that [18F]FES can be used as a valuable PET tracer to determine the tissue levels of ER in patients with breast cancer and may emerge as a valuable tool to predict which patients with primary, recurrent, or metastatic breast cancer will respond to hormone therapy [3, 4]. Here, ESR1 is linked to breast carcinoma.